Biocytok and Moonlight Bio Collaborate to Advance Cell Therapy with Fully Human Antibody Library
Biocytogen (Beijing) Pharmaceutical Technology a globally focused biotechnology company known for its innovative platforms in drug discovery and development, has entered into a strategic collaboration agreement with Moonlight Bio, Inc., a Seattle-based biotech firm recognized for its expertise in advanced cell therapy technologies. This partnership reflects a shared commitment to accelerating the development of next-generation cell therapies, particularly aimed at addressing some of the most difficult-to-treat and refractory cancers.
The collaboration brings together two organizations with complementary strengths. Biocytogen has established itself as a leader in antibody discovery, particularly through its proprietary fully human antibody library. This platform is designed to generate high-quality antibody candidates that can be used across a wide range of therapeutic modalities. On the other hand, Moonlight Bio specializes in the development of innovative cell therapies, focusing on engineering advanced cellular treatments capable of targeting complex disease mechanisms. By combining these capabilities, the two companies aim to create more effective therapeutic solutions for patients who currently have limited treatment options.
Refractory cancers—those that do not respond to existing therapies or that relapse after treatment—remain a significant challenge in oncology. Traditional approaches such as chemotherapy, radiation, and even some targeted therapies often fail to produce durable responses in these cases. As a result, there is a growing need for novel treatment strategies that can overcome resistance mechanisms and deliver more precise, long-lasting effects. Cell therapies, including engineered immune cells, have emerged as a promising avenue in this regard, offering the potential to directly target and eliminate cancer cells.
The strategic alliance between Biocytogen and Moonlight Bio is specifically designed to address these challenges. Under the terms of the agreement, Biocytogen will contribute its fully human antibody molecules, which are developed to target specific disease-related antigens. These antibodies can serve as critical components in the design of cell therapies, enabling engineered cells to recognize and attack cancer cells with high specificity. Moonlight Bio will then take the lead in advancing these candidates through preclinical development, applying its expertise in cell engineering, functional validation, and therapeutic optimization.
Dr. Shen Yuelei, Chairman and CEO of Biocytogen, emphasized the significance of this collaboration in advancing the company’s broader strategic vision. He noted that partnering with Moonlight Bio represents an important step in expanding the application of Biocytogen’s antibody discovery platform beyond traditional therapeutic formats. While antibodies have historically been used in standalone biologic drugs, their integration into cell therapies opens up new possibilities for enhancing treatment efficacy and precision.
According to Dr. Shen, the collaboration also highlights the versatility and scalability of Biocytogen’s proprietary platform. The company’s fully human antibody library is designed to provide “off-the-shelf” solutions, meaning that high-quality antibody candidates can be rapidly identified and deployed for various therapeutic applications. This capability is particularly valuable in the fast-evolving field of cell therapy, where speed and adaptability are critical to staying ahead of emerging scientific and clinical challenges.
Moonlight Bio, for its part, brings a deep understanding of cell therapy development, including the design and engineering of next-generation cellular products. The company focuses on leveraging cutting-edge technologies to enhance the functionality, persistence, and safety of therapeutic cells. By incorporating Biocytogen’s antibodies into its cell therapy platforms, Moonlight Bio aims to create more targeted and effective treatments capable of addressing unmet medical needs in oncology.
The collaboration is expected to generate a pipeline of novel cell therapy candidates targeting a range of cancer types. These therapies will be designed to overcome common limitations associated with current treatments, such as tumor heterogeneity, immune evasion, and drug resistance. Through rigorous preclinical testing, the partners aim to identify candidates with strong therapeutic potential, paving the way for future clinical development.
In addition to its scientific and clinical implications, the partnership also reflects broader trends in the biotechnology industry. Increasingly, companies are recognizing the value of collaboration in driving innovation and accelerating development timelines. By combining specialized expertise and resources, partnerships like this one can help reduce risk, improve efficiency, and ultimately bring new therapies to patients more quickly.
The integration of antibody discovery with cell therapy development represents a particularly promising area of innovation. Antibodies can be used to guide engineered cells to specific targets, enhancing their ability to distinguish between healthy and diseased tissues. This precision is critical for minimizing side effects and improving overall treatment outcomes. Furthermore, the use of fully human antibodies reduces the risk of immunogenicity, which can be a concern with non-human or partially humanized molecules.
As the collaboration progresses, both companies are expected to work closely together to optimize the design and development of their therapeutic candidates. This includes selecting the most promising targets, refining antibody-cell constructs, and conducting comprehensive preclinical studies to evaluate safety and efficacy. The ultimate goal is to advance these therapies into clinical trials and, eventually, to make them available to patients in need.
The partnership also underscores the importance of innovation in addressing complex diseases like cancer. Despite significant advances in recent years, many patients still face limited treatment options, particularly in cases of advanced or resistant disease. By exploring new therapeutic approaches and leveraging cutting-edge technologies, companies like Biocytogen and Moonlight Bio are helping to push the boundaries of what is possible in medicine.
In conclusion, the strategic collaboration between Biocytogen and Moonlight Bio represents a significant step forward in the development of next-generation cell therapies. By combining Biocytogen’s expertise in fully human antibody discovery with Moonlight Bio’s capabilities in cell therapy engineering, the partnership aims to create innovative treatments for some of the most challenging cancers. Through this joint effort, the companies hope to overcome existing limitations in cancer therapy, accelerate the development of transformative treatments, and ultimately bring new hope to patients worldwide.
About Biocytogen
Biocytogen (Stock Code: 688796.SH; 02315.HK) is an international biotechnology company driven by innovative technologies, committed to becoming a global origin of new drugs. With its proprietary gene-editing technology at its core, the company has built a dual-engine platform of “fully human antibody molecular library + target humanized mouse library,” systematically accelerating global drug development. Biocytogen has independently developed the RenMice® fully human antibody platform (covering RenMab® , RenLite® , RenNano® , RenTCR™, and RenTCR mimic™) for the discovery of therapeutic fully human monoclonal antibodies, bispecific/multispecific antibodies, bispecific antibody ADCs, nanoantibodies, and TCR-like antibodies. Around 1000+ potential druggable targets, the company is advancing its large-scale antibody discovery program—”Thousands of Mice, Thousands of Antibodies™”—which has already constructed a library of over 1 million real fully human antibody sequences and is open to global collaboration. As of December 31, 2025, Biocytogen has signed over 350 drug collaboration/licensing/transfer agreements. Its subsidiary brand, BioCyto Animals, has established thousands of gene-edited animal/cell models and possesses a world-leading library of targeted humanized mice. It provides global clients with end-to-end support in preclinical pharmacology and efficacy studies, gene editing services, and model construction. Headquartered in Beijing, BioCytogen has branches in China (Haimen, Jiangsu; Shanghai), the United States (Boston, San Francisco, San Diego), and Heidelberg, Germany, forming a global R&D and operations network
